一因子(纤原蛋白)纯化工艺的专利(英文)0803.doc

一因子(纤原蛋白)纯化工艺的专利(英文)0803.doc

  1. 1、本文档共35页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
一因子(纤原蛋白)纯化工艺的专利(英文)0803一因子(纤原蛋白)纯化工艺的专利(英文)0803

PROCESSES FOR THE PREPARATION OF FIBRINOGEN ? Bibliographic data ? ? Description ? ? Claims ? ? Mosaics ? ? Original document ? ? INPADOC legal status ? ? ? Description of WO2004007533 ??? Desc/Clms Page number 1 Processes for the preparation of fibrinogen The present invention relates to processes for the purification of fibrinogen, and to readily solubilised fibrinogen preparations. Fibrinogen is a blood plasma protein which is concerned in clot formation. It is converted into fibrin monomer by the action of the plasma protease thrombin. Fibrin monomers cluster together to form a weak clot and are then cross-linked by the action of activated factor XIII (i. e. factorXIIIa) to a form a stronger clot. Fibrinogen is used in therapy in combination with thrombin in the so-called fibrin sealants to achieve haemostasis, to seal wounds and for the controlled adhesion of tissue. Fibrinogen concentrates are also used for replacement therapy treatment of patients with fibrinogen deficiency(afibrinogenaemia) which may be inherited or acquired. For all clinical applications, it is important to have highly pure fibrinogen in order to minimise any undesirable side effects resulting from, for example, the presence of unwanted contaminating proteins. In particular, it is desirable for fibrinogen preparations for clinical use to be free of plasminogen and plasmin(Blomback B. , Blomback M. ,Purification of human and bovine fibrinogen, Arkiv for Kemi 1956; 10: 415-443, and Mosesson M. W. ,The preparation of human fibrinogen free of plasminogen, Biochim Biophys Acta 1962,57 : 204-213). Plasminogen is the inactive precursor of plasmin, a fibrinolytic enzyme which digests fibrin clots. Therefore the presence of plasminogen in a fibrinogen preparation intended for use in vivo is undesirable because any plasmin generated from the plasminogen at the site of clot formation may thendestabilise the clot. Plasminogen tends to c

您可能关注的文档

文档评论(0)

cxiongxchunj + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档